Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 639667 in Healthy Male Subjects (Single-blind, Partially Randomised, Placebo-controlled Parallel Group Design)
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2014
At a glance
- Drugs BI 639667 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 14 Jul 2014 Planned End Date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 14 Jul 2014 Planned primary completion date changed from 1 Sep 2014 to 1 Oct 2014 as reported by ClinicalTrials.gov record.
- 13 May 2014 New trial record